Skip to main content

Table 2 Glycemic outcomes, lipids and liver enzymes in patients with IGT, at baseline and after 12 weeks’ treatment or placebo

From: Cassia cinnamon does not change the insulin sensitivity or the liver enzymes in subjects with impaired glucose tolerance

Variables Baseline    12 wk.    
  Control Treated p-value Control p-value Treated p-value
Fasting-glucose (mmol/l) 6.7 ± 0.4 6.0 ± 0.3 0.370 6.1 ± 0.4 0.205 6.1 ± 0.4 0.735
Fasting-insulin (mlE/l) 11.1 ± 2.0 9.8 ± 2.1 0.481 8.5 ± 1.6 0.034* 9.0 ± 2.5 0.284
HbA1c (mmol/mol) 40.1 ± 2.4 39.6 ± 1.3 0.815 40.1 ± 1.8 0.786 40.2 ± 1.6 0.320
Cholesterol (mmol/l) 4.5 ± 0.2 4.9 ± 0.4 0.673 4.4 ± 0.2 0.670 4.6 ± 0.3 0.482
LDL Cholesterol (mmol/l) 2.7 ± 0.2 3.2 ± 0.4 0.606 2.6 ± 0.3 0.528 2.9 ± 0.2 0.553
HDL Cholesterol (mmol/l) 1.5 ± 0.1 1.4 ± 0.1 0.888 1.5 ± 0.1 0.774 1.4 ± 0.1 0.414
Triglycerides (mmol/l) 1.1 ± 0.1 1.1 ± 0.1 0.888 1.0 ± 0.2 0.686 1.0 ± 0.1 0.101
ASAT (μkat/l) 0.38 ± 0.04 0.40 ± 0.05 0.888 0.38 ± 0.04 0.752 0.41 ± 0.05 0.445
ALAT (μkat/l) 0.39 ± 0.07 0.50 ± 0.09 0.481 0.38 ± 0.08 0.528 0.49 ± 0.09 0.799
ALP (μkat/l) 0.89 ± 0.05 1.04 ± 0.13 0.541 0.86 ± 0.06 0.161 1.10 ± 1.28 0.128
GT (μkat/l) 0.37 ± 0.07 0.58 ± 0.15 0.370 0.36 ± 0.06 0.674 0.71 ± 0.25 0.313
Bilirubin (μmol/l) 9.2 ± 1.1 9.9 ± 1.6 0.963 8.5 ± 1.1 0.197 11.6 ± 2.0 0.087
Pk (INR) 1.04 ± 0.02 1.0 ± 0.02 0.888 1.01 ± 0.02 0.157 1.0 ± 0.02 0.317
  1. Significant differences between the control and treated group in glycemic outcomes, lipids and liver enzymes were evaluated at baseline with the Mann-Whitney U test.
  2. Significant differences within the groups in glycemic outcomes, lipids and liver enzymes were evaluated at 12 wk. with the Wilcoxons signed rank test, *p < 0.05.
  3. Values are reported as means ± SD.